Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant miceGRITZAPIS, Angelos D; VOUTSAS, Ioannis F; BAXEVANIS, Constantin N et al.Cancer immunology and immunotherapy. 2012, Vol 61, Num 3, pp 397-407, issn 0340-7004, 11 p.Article

Peptide Vaccination Breaks Tolerance to HER-2/neu by Generating Vaccine-Specific FasL⁺ CD4⁺ T Cells: First Evidence for Intratumor Apoptotic Regulatory T CellsGRITZAPIS, Angelos D; VOUTSAS, Loannis F; LEKKA, Eftychia et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 7, pp 2686-2696, issn 0008-5472, 11 p.Article

HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3⁺CD56⁺ (natural killer T) lymphocytesBAXEVANIS, Constantin N; GRITZAPIS, Angelos D; TSITSILONIS, Ourania E et al.International journal of cancer. 2002, Vol 98, Num 6, pp 864-872, issn 0020-7136Article

Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assayGRITZAPIS, Angelos D; BAXEVANIS, Constantin N; MISSITZIS, Ioannis et al.Breast cancer research and treatment. 2003, Vol 80, Num 1, pp 1-13, issn 0167-6806, 13 p.Article

Induction of potent CD4⁺ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-key moiety of the invariant chainVOUTSAS, Ioannis F; GRITZAPIS, Angelos D; MAHAIRA, Louisa G et al.International journal of cancer. 2007, Vol 121, Num 9, pp 2031-2041, issn 0020-7136, 11 p.Article

In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the γ-chain from Fc(ε) RIMAMALAKI, Avgi; GRITZAPIS, Angelos D; KRETSOVALI, Androniki et al.Cancer immunology and immunotherapy. 2003, Vol 52, Num 8, pp 513-522, issn 0340-7004, 10 p.Article

HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor propertiesGRITZAPIS, Angelos D; FRIDMAN, Arthur; PEREZ, Sonia A et al.Vaccine. 2010, Vol 28, Num 1, pp 162-170, issn 0264-410X, 9 p.Article

Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapyLEKKA, Eftychia; GRITZAPIS, Angelos D; PEREZ, Sonia A et al.Cancer immunology and immunotherapy. 2010, Vol 59, Num 5, pp 715-727, issn 0340-7004, 13 p.Article

Efficacy of novel culture environments on the ex vivo expansion kinetics of cord blood progenitor cellsCACOULIOS, Nike T; GRITZAPIS, Angelos D; TSITSILONIS, Athanasios E et al.Haematologica (Roma). 2002, Vol 87, Num 3, pp 320-321, issn 0390-6078Article

HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4⁺T cell clonesPEREZ, Sonia A; SOTIROPOULOU, Panagiota A; SOTIRIADOU, Nectaria N et al.Cancer immunology and immunotherapy. 2002, Vol 50, Num 11, pp 615-624, issn 0340-7004Article

A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survivalPEREZ, Sonia A; MAHAIRA, Louisa G; DEMIRTZOGLOU, Fillio J et al.Blood. 2005, Vol 106, Num 1, pp 158-166, issn 0006-4971, 9 p.Article

A novel myeloid-like NK cell progenitor in human umbilical cord bloodPEREZ, Sonia A; SOTIROPOULOU, Panagiota A; GKIKA, Dimitra G et al.Blood. 2003, Vol 101, Num 9, pp 3444-3450, issn 0006-4971, 7 p.Article